2. Signaling Pathways
  3. Immunology/Inflammation
  4. Scavenger Receptor Class B type I (SR-BI）
  5. Scavenger Receptor Class B type I (SR-BI） Inhibitor

Scavenger Receptor Class B type I (SR-BI） Inhibitor

Scavenger Receptor Class B type I (SR-BI） Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-163541
    SMS121
    		Inhibitor 99.06%
    SMS121 is a CD36 inhibitor with a KD values of about 5 µM. SMS121 reduces the uptake of lipids and inhibits cell viability in acute myeloid leukemia cells. SMS121 has antitumor activity.
  • HY-19900
    ITX5061
    		Inhibitor 99.69%
    ITX5061 is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 increases HDL-C levels by inhibiting SR-BI activity. ITX5061 also moderately elevates ApoA-I levels. ITX5061 reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 can be used in the research of atherosclerosis.
  • HY-P990352
    Anti-CD36 Antibody
    		Inhibitor 99.43%
    Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P991911
    PLT012
    		Inhibitor
    PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8+ tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8+ T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research.
  • HY-119770
    HDL376
    		Inhibitor 98.62%
    HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease.
  • HY-122068
    ITX5061 free base
    		Inhibitor
    ITX5061 free base is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 free base increases HDL-C levels by inhibiting SR-BI activity. ITX5061 free base also moderately elevates ApoA-I levels. ITX5061 free base reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 free base can be used in the research of atherosclerosis.
  • HY-120433
    BLT-3
    		Inhibitor
    BLT-3 is an inhibitor of scavenger receptor class B type I (SR-BI) that exerts reversible, non-cell-type-specific inhibitory effects on SR-BI-mediated lipid transport. BLT-3 inhibits SR-BI-mediated selective lipid uptake from HDL as well as cholesterol efflux from cells to HDL. BLT-3 enhances the binding of HDL to SR-BI. BLT-3 is applicable to research related to atherosclerosis and coronary heart disease.
  • HY-19616
    ML278
    		Inhibitor
    ML278 is an efficient, low toxicity, and plasma stable SR-BI (IC50 = 6 nM) lipid uptake inhibitor. ML278 enhances HDL binding while inhibiting SR-BI mediated lipid uptake. ML278 can be used for research on metabolic conditions.
  • HY-124666
    ML279
    		Inhibitor
    ML279 is a potent scavenger receptor, class B, type I (SR-BI) inhibitor. ML279 can inhibit SR-BI-mediated lipid uptake by stabilizing the binding of HDL to SR-BI (EC50 = 0.27 μM). ML279 can be used for the researches of infection and cardiovascular disease, such as atherosclerosis and HCV infection.